Table 1.
PCR Signature Erosion Tool (PSET) analysis of ebolavirus PCR assay signatures.
| Assay # | Assay ID | Intended Target Species | Gene Target | Species/Strain of Hits | Amplicon Length (bps) | Assay Hit | Perfect Assay Hits | Percentage of Perfect | Amplicon Hits | Perefect Amplicon Hit | Percentage of Perfect | True-Positive | False-Negative | False-Positive | True-Negative | Report * |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sig 1 | EBOV | NP | EBOV | 124 | 135 | 132 | 97.8 | 135 | 11 | 8.1 | 135 | 0 | 0 | 0 | Pass |
| 2 | EbolaZaire-MGB | EBOV | NP | EBOV | 76 | 135 | 134 | 99.3 | 135 | 124 | 91.9 | 135 | 0 | 0 | 0 | Pass |
| 3 | Sig 3 | EBOV | NP | EBOV | 49 | 135 | 135 | 100.0 | 135 | 125 | 92.6 | 135 | 0 | 0 | 0 | Pass |
| 4 | EboZNP | EBOV | NP | EBOV | 80 | 136 | 22 | 16.2 | 136 | 19 | 14.0 | 136 | 0 | 0 | 0 | Pass |
| 4 | EboZNP | EBOV | NP | SUDV | 80 | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 11 | |
| 5 | ZAI-NP | EBOV | NP | EBOV | 268 | 148 | 123 | 83.1 | 148 | 10 | 6.8 | 148 | 0 | 0 | 0 | Pass |
| 6 | Ebola MGB-EBOV | EBOV | NP | EBOV | 79 | 148 | 23 | 15.5 | 148 | 11 | 7.4 | 148 | 0 | 0 | 0 | Pass |
| 7 | ENZ | EBOV | NP | EBOV | 70 | 148 | 32 | 21.6 | 148 | 32 | 21.6 | 148 | 0 | 0 | 0 | Pass |
| 10 | EBO-GP-1 | EBOV | GP | EBOV | 579 | 152 | 0 | 0 | 152 | 5 | 3.3 | 152 | 0 | 0 | 0 | Fail |
| 10 | EBO-GP-1 | EBOV | GP | RESTV | 579 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | |
| 12 | ZebovGP | EBOV | GP | EBOV | 64 | 153 | 13 | 8.5 | 153 | 13 | 8.5 | 153 | 0 | 0 | 0 | Pass |
| 13 | Ebola Zaire-TM | EBOV | GP | EBOV | 80 | 144 | 13 | 9.0 | 153 | 13 | 8.5 | 144 | 9 | 0 | 0 | Fail |
| 16 | Filo AB | pan-Filo | L | EBOV | 419 | 135 | 0 | 0 | 135 | 12 | 8.9 | 135 | 0 | 0 | 0 | Pass |
| 16 | Filo AB | pan-Filo | L | MARV | 419 | 55 | 0 | 0 | 0 | 0 | 0 | 55 | 0 | 0 | 0 | |
| 16 | Filo AB | pan-Filo | L | SUDV | 419 | 12 | 0 | 0 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | |
| 17 | GAB-1 | EBOV | L | EBOV | 353 | 135 | 17 | 12.6 | 135 | 12 | 8.9 | 135 | 0 | 0 | 0 | Pass |
| 19 | Ebola BDBV-MGB | BDBV | NP | BDBV | 74 | 5 | 1 | 20.0 | 5 | 1 | 20.0 | 5 | 0 | 0 | 0 | Pass |
| 20 | Ebola BDBV-TM | BDBV | NP | BDBV | 74 | 5 | 1 | 20.0 | 5 | 1 | 20.0 | 5 | 0 | 0 | 0 | Pass |
| 21 | Ebola TAFV-MGB | TAFV | GP | TAFV | 64 | 2 | 1 | 50.0 | 2 | 1 | 50.0 | 2 | 0 | 0 | 0 | Pass |
| 22 | Ebola TAFV-TM | TAFV | GP | TAFV | 79 | 2 | 2 | 100.0 | 2 | 2 | 100.0 | 2 | 0 | 0 | 0 | Pass |
| 23 | Reston | RESTV | NP | RESTV | 337 | 8 | 8 | 100.0 | 8 | 3 | 37.5 | 8 | 0 | 0 | 0 | Pass |
| 24 | Ebola-MGB-RESTV | RESTV | GP | RESTV | 97 | 8 | 2 | 25.0 | 8 | 2 | 25.0 | 8 | 0 | 0 | 0 | Pass |
| 24 | Ebola-MGB-RESTV | RESTV | GP | EBOV | 97 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 | 9 | |
| 25 | Ebola Reston-TM | RESTV | VP40 | RESTV | 80 | 8 | 2 | 25.0 | 8 | 2 | 25.0 | 8 | 0 | 0 | 0 | Pass |
| 26 | Ebola Reston-MGB | RESTV | GP | RESTV | 55 | 11 | 10 | 90.9 | 12 | 10 | 83.3 | 11 | 1 | 0 | 0 | Fail |
| 27 | Ebola Sudan-MGB | SUDV | NP | SUDV | 80 | 11 | 10 | 90.9 | 11 | 10 | 90.9 | 11 | 0 | 0 | 0 | Pass |
| 27 | Ebola Sudan-MGB | SUDV | NP | RESTV | 80 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 8 | |
| 27 | Ebola Sudan-MGB | SUDV | NP | EBOV | 80 | 0 | 0 | 0 | 148 | 0 | 0 | 0 | 0 | 0 | 148 | |
| 28 | Ebola MGB-SUDV | SUDV | NP | SUDV | 81 | 11 | 7 | 63.6 | 11 | 2 | 18.2 | 11 | 0 | 0 | 0 | Pass |
| 29 | Sudan | SUDV | NP | SUDV | 89 | 11 | 10 | 90.9 | 11 | 10 | 90.9 | 11 | 0 | 0 | 0 | Pass |
| 30 | Ebola Sudan-TM | SUDV | GP | SUDV | 77 | 14 | 9 | 64.3 | 14 | 9 | 64.3 | 14 | 0 | 0 | 0 | Pass |
* Pass/Fail call for each assay based on 90/90 and 85/90 rule for assay hit and amplicon hit, respectively. Number of sequences is limited in non-Zaire assays and, hence, does not represent the true genetic diversity of the species and, hence, the true success of the non-Zaire assays.